Resources from the same session
508MO - Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study
Presenter: Myung-Ju Ahn
Session: Mini oral session 1: Thoracic cancer
Resources:
Abstract
Slides
Webcast
509MO - Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
Presenter: Myung-Ju Ahn
Session: Mini oral session 1: Thoracic cancer
Resources:
Abstract
Slides
Webcast
510MO - Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINY–Lung02 (DL-02)
Presenter: Yasushi Goto
Session: Mini oral session 1: Thoracic cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant 508MO, 509MO and 510MO
Presenter: Lizza Hendriks
Session: Mini oral session 1: Thoracic cancer
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mini oral session 1: Thoracic cancer
Resources:
Webcast
LBA13 - Dostarlimab + chemotherapy (CT) vs pembrolizumab + CT in metastatic non-squamous non-small cell lung cancer (NSCLC): Updated Asian subgroup analyses of the PERLA trial
Presenter: Jin Seok Ahn
Session: Mini oral session 1: Thoracic cancer
Resources:
Abstract
Slides
Webcast
511MO - A phase I study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: Jifeng Feng
Session: Mini oral session 1: Thoracic cancer
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mini oral session 1: Thoracic cancer
Resources:
Webcast